Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186498
Status:
COMPLETED
Last Update Posted:
2019-09-27
First Post:
2005-09-14
Brief Title:
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy
Detailed Description:
The primary objective of this study is to determine whether the novel NMDA antagonist memantine FDA approved for use in moderate to severe alzheimers dementia may reduce the neurocognitive deficits associated with right unilateral ECT treatments in patients receiving ECT for a severe and relatively refractory Major Depressive episode
Our hypothesis is that the use of an NMDA antagonist would reduce intracellular calcium levels and glutamatergic stimulation during ECT This reduction in excitatory stimulation during ECT would reduce hippocampal and prefrontal neuronal endangerment and dysfunction thereby reducing cognitive impairment associated with right unilateral ECT treatments We also hypothesize that ACTH and cortisol levels will correlate with neurocognitive impairment in placebo treated subjects but not in the memantine treated individuals
Our hypothesis is that the use of an NMDA antagonist would reduce intracellular calcium levels and glutamatergic stimulation during ECT This reduction in excitatory stimulation during ECT would reduce hippocampal and prefrontal neuronal endangerment and dysfunction thereby reducing cognitive impairment associated with right unilateral ECT treatments We also hypothesize that ACTH and cortisol levels will correlate with neurocognitive impairment in placebo treated subjects but not in the memantine treated individuals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None